New Partners Hunt Breakthroughs for Kids With Rare Brain Disorders

Angelini Pharma and Quiver Bioscience have joined forces to look for new medicines that could help children suffering from hard‑to‑treat genetic epilepsies. The deal gives Quiver a chance to use Angelini’s long experience in brain drugs while Angelini gains access to Quiver’s cutting‑edge AI tools and human neuron models. Under the multi‑year contract, Quiver will receive an upfront payment and extra money for hitting key research milestones. Angelini gets the right to use any data that comes out of their joint studies, and Quiver can earn up to $120 million if Angelini decides to develop a drug based on their discoveries. The partnership focuses on Developmental and Epileptic Encephalopathies, a group of rare childhood diseases that cause severe seizures and learning problems. Although some new treatments exist, many patients still need better options because the exact ways that gene mutations damage brain cells are not fully understood.Quiver’s technology uses engineered human neurons, single‑cell recordings, and machine learning to map how specific gene changes alter brain cell behavior. By linking these functional changes with the underlying biology, the teams hope to spot new targets for therapy that could work across several of these disorders. Angelini’s chief scientific officer said the collaboration should generate a wealth of data that is far richer than what has been seen before in this field. Meanwhile, Quiver’s CEO highlighted that the partnership will translate their experimental findings into real medicines for a condition that urgently needs innovation. The agreement follows a series of other deals Angelini has made in the past two years, which have expanded its reach and strengthened its focus on brain health. Both companies see the partnership as a step toward expanding their global presence and adding promising new candidates to their pipelines.